Key Highlights
- Eric Olson named Chief Business Officer at Stoke Therapeutics
- Olson brings over $15 billion in transaction experience from Alnylam and Takeda
- Will lead corporate strategy and business development at Stoke Therapeutics
Source: Business Wire
Notable Quotes
- “We see a significant opportunity to expand the potential of Stoke’s first-in-class, disease-modifying approach to the treatment of many genetic diseases…” — Edward M. Kaye, M.D., CEO at Stoke Therapeutics
- “I’ve had the opportunity to work on significant advances in RNA therapeutics and rare diseases and look forward to working with the leadership team at Stoke…” — Eric Olson, Chief Business Officer at Stoke Therapeutics
SoHC's Take
The appointment of Eric Olson as Chief Business Officer signals Stoke Therapeutics’ commitment to aggressive growth and innovation. Olson’s extensive experience in business development within the life sciences industry, especially in RNA medicine and rare genetic diseases, aligns perfectly with Stoke’s mission of addressing severe diseases through RNA-based therapies. His leadership will be instrumental as the company continues to advance its TANGO platform and expand into new therapeutic areas, including the central nervous system and ophthalmology.
